Patient-Reported Outcome Measures in Oncology Drugs Approved by the European Medicines Agency, 2017-2021

Oriana Ciani; Michela Meregaglia; Francesco De Lorenzo; Francesco Perrone; Carmine Pinto

doi:10.1001/jamanetworkopen.2022.51564

Patient-Reported Outcome Measures in Oncology Drugs Approved by the European Medicines Agency, 2017-2021

JAMA Netw Open. 2023 Jan 3;6(1):e2251564. doi: 10.1001/jamanetworkopen.2022.51564.

Authors

Oriana Ciani¹, Michela Meregaglia¹, Francesco De Lorenzo², Francesco Perrone^{3

4}, Carmine Pinto^{5

6}

Affiliations

¹ Center for Research on Health and Social Care Management, SDA Bocconi, Milan, Italy.
² Italian Federation of Oncological Voluntary Associations, Rome, Italy.
³ Clinical Trials Unit, National Cancer Institute, Naples, Italy.
⁴ Italian Association of Medical Oncology, Milan, Italy.
⁵ Comprehensive Cancer Centre, Istituto di Ricovero e Cura a Carattere Scientifico-Azienda Unità Sanitaria Locale Reggio Emilia, Italy.
⁶ Federation of Italian Cooperative Oncology Groups, Florence, Italy.

No abstract available

Plain language summary

This cross-sectional study investigates the use of patient-reported outcome measures in new marketing authorizations for oncology drugs approved by the European Medicines Agency (EMA) between 2017 and 2021.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / therapeutic use
Humans
Neoplasms* / drug therapy
Patient Reported Outcome Measures

Substances

Antineoplastic Agents